Author

V. Cardoso Soares

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Research Focus:drug response / drug discovery· 2 Research Focus:host-pathogen & immune response· 2 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1

Frequent Co-Authors

C. Q. Sacramento· 3 shared J. R. Temerozo· 3 shared N. Fintelman-Rodrigues· 3 shared P. T. Bozza· 3 shared T. M. L. Souza· 3 shared C. S. de Freitas· 2 shared F. A. Bozza· 2 shared G. Vitoria· 2 shared

Activity by Year

2020-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

C. Q. Sacramento

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Cell BiologybioRxivPreprintFeb 20, 2021

WIN 55,212-2 shows anti-inflammatory and survival properties in human iPSC-derived cardiomyocytes infected with SARS-CoV-2

L. G. H. S. Aragao, J. T. Oliveira, J. R. Temerozo…·S. Rehen

This study examines the effects of the cannabinoid agonist WIN 55,212-2 on inflammation and cell survival in human iPSC-derived cardiomyocytes infected with SARS-CoV-2, finding reduced cytokine levels and cytotoxic damage.

DOI 10.1101/2021.02.20.431855

humanbulk RNA-seq

𝕏 PostBluesky

MicrobiologyAntimicrobial Agents and ChemotherapyPeer-reviewedSep 21, 2020

Atazanavir inhibits SARS-CoV-2 replication and pro-inflammatory cytokine production

N. Fintelman-Rodrigues, C. Q. Sacramento, C. Ribeiro Lima…·T. M. L. Souza

This study shows that atazanavir inhibits SARS-CoV-2 replication and reduces pro-inflammatory cytokine production in vitro.

DOI 10.1128/aac.00825-20

humanexperimental assay

𝕏 PostBluesky

MicrobiologybioRxivPreprintJun 15, 2020

The in vitro antiviral activity of the anti-hepatitis C virus (HCV) drugs daclatasvir and sofosbuvir against SARS-CoV-2

C. Q. Sacramento, N. Fintelman-Rodrigues, J. R. Temerozo…·T. M. L. Souza

This study evaluates the antiviral activity of daclatasvir and sofosbuvir against SARS-CoV-2 in vitro, showing inhibition of viral replication and associated pathologies.

DOI 10.1101/2020.06.15.153411

humanexperimental assay

𝕏 PostBluesky